X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (23) 23
animals (16) 16
humans (16) 16
female (11) 11
mice (11) 11
pharmacology & pharmacy (8) 8
adult (7) 7
cell division - drug effects (7) 7
drug resistance (7) 7
middle aged (7) 7
aged (6) 6
antineoplastic agents - pharmacology (6) 6
cisplatin (6) 6
tumor cells, cultured - drug effects (6) 6
cancer (5) 5
cell line (5) 5
structure-activity relationship (5) 5
time factors (5) 5
tumor cells, cultured (5) 5
bryostatins (4) 4
carcinoma (4) 4
drug screening assays, antitumor (4) 4
expression (4) 4
glutathione transferase - metabolism (4) 4
growth (4) 4
leukemia p388 - drug therapy (4) 4
macrolides (4) 4
male (4) 4
ovarian cancer (4) 4
ovarian neoplasms - pathology (4) 4
protein-kinase-c (4) 4
aged, 80 and over (3) 3
agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic agents, phytogenic - chemistry (3) 3
antineoplastic agents, phytogenic - pharmacology (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
biochemistry & molecular biology (3) 3
biomarkers, tumor - metabolism (3) 3
cell-line (3) 3
chemistry, medicinal (3) 3
chemistry, organic (3) 3
cis-diamminedichloroplatinum (3) 3
differentiation (3) 3
flow cytometry (3) 3
glutathione - metabolism (3) 3
indoles - pharmacology (3) 3
infusions, intravenous (3) 3
isoenzymes - metabolism (3) 3
lactones - administration & dosage (3) 3
leukemia p388 - metabolism (3) 3
ovarian neoplasms - drug therapy (3) 3
ovarian neoplasms - metabolism (3) 3
prognosis (3) 3
regular (3) 3
regular article (3) 3
resistance (3) 3
temperature (3) 3
adriamycin (2) 2
anticancer agent (2) 2
antimitotic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - pharmacokinetics (2) 2
antineoplastic agents, phytogenic - isolation & purification (2) 2
antineoplastic agents, phytogenic - toxicity (2) 2
apoptosis (2) 2
assay (2) 2
bryostatin (2) 2
carboplatin - administration & dosage (2) 2
cell survival - drug effects (2) 2
cell-lines (2) 2
chemosensitivity (2) 2
chemotherapy (2) 2
chromatography, high pressure liquid (2) 2
chronic lymphocytic-leukemia (2) 2
combretastatin a-4 (2) 2
cyclophosphamide (2) 2
daunorubicin - metabolism (2) 2
daunorubicin - pharmacology (2) 2
daunorubicin - therapeutic use (2) 2
design (2) 2
dna, neoplasm - analysis (2) 2
dna, neoplasm - metabolism (2) 2
dose-response relationship, drug (2) 2
drug interactions (2) 2
drug stability (2) 2
drug-resistance (2) 2
enzyme inhibitors - pharmacology (2) 2
flow-cytometry (2) 2
gene (2) 2
glutathione transferase - antagonists & inhibitors (2) 2
immunohistochemistry (2) 2
in-vitro (2) 2
infusion pumps (2) 2
lactones - adverse effects (2) 2
lactones - pharmacology (2) 2
leukemia (2) 2
leukemia l1210 - genetics (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Dalton Transactions, ISSN 1477-9226, 2010, Volume 39, Issue 14, pp. 3509 - 3520
Journal Article
Angewandte Chemie - International Edition, ISSN 1433-7851, 11/2006, Volume 45, Issue 45, p. 7489
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/1995, Volume 71, Issue 4, pp. 705 - 711
A series of stilbenes, based on combretastatin A-4, were synthesised. A structure-activity study was carried out to characterise the interaction of these... 
Combrestatins | Structure-activity | Tubulin | STRUCTURE-ACTIVITY | POTENT | ONCOLOGY | ANALOGS | AGENTS | TUBULIN | CALF BRAIN TUBULIN | COMBRESTATINS
Journal Article
Cancer Research, ISSN 0008-5472, 01/2000, Volume 60, Issue 19, pp. 5470 - 5478
Journal Article
British Journal of Cancer, ISSN 0007-0920, 08/1995, Volume 72, Issue 2, pp. 461 - 468
Bryostatin 1 is a macrocyclic lactone derived from the marine invertebrate Bugula neritina. In vitro, bryostatin 1 activates protein kinase C (PKC), induces... 
Protein kinase C | Immunomodulation | Bryostatin | Cancer | PROTEIN-KINASE-C | ADVANCED CANCER | MACROCYCLIC LACTONE | PROTEIN KINASE C | ANTICANCER AGENT | HL-60 CELLS | CANCER | IMMUNOMODULATION | BRYOSTATIN | INVIVO ACTIVITY | ONCOLOGY | GROWTH | CHRONIC LYMPHOCYTIC-LEUKEMIA | DIFFERENTIATION | PHORBOL ESTER
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1990, Volume 26, Issue 1, pp. 79 - 81
Combretastatin A4, a novel anti-mitotic agent was effective against two P388 cell lines with acquired resistance to daunorubicin. In contrast, Combretastatin... 
Cell Survival - drug effects | Drug Resistance - genetics | Animals | Drug Interactions | Vinca Alkaloids - pharmacology | Tumor Cells, Cultured - drug effects | Daunorubicin - pharmacology | Mice | Stilbenes - pharmacology | Antineoplastic Agents, Phytogenic - pharmacology | Leukemia P388 - genetics
Journal Article
British Journal of Cancer, ISSN 0007-0920, 1994, Volume 69, Issue 3, pp. 609 - 612
Journal Article
International Journal of Gynecological Cancer, ISSN 1048-891X, 07/1995, Volume 5, Issue 4, pp. 269 - 274
5T4 oncofetal antigen is defined by a monoclonal antibody raised against human placental trophoblast, and recognizes a 72 kD glycoprotein expressed in many... 
5T4 oncofetal antigen | ovarian carcinoma | survival | SURVIVAL | DESIGN | REQUIRING PROLONGED OBSERVATION | ONCOLOGY | PATIENT | 5T4 ONCOFETAL ANTIGEN | OVARIAN CARCINOMA | OBSTETRICS & GYNECOLOGY
Journal Article
British Journal of Cancer, ISSN 0007-0920, 05/1991, Volume 63, Issue 5, pp. 711 - 714
The metallothionein content of ovarian tumours is considerably higher than that found in normal ovaries (> 100-fold differences in mean values, P < 0.001).... 
CISPLATIN | ONCOLOGY | RESISTANCE | EXPRESSION | CANCER | CELL-LINE | CIS-DICHLORODIAMMINEPLATINUM
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/1998, Volume 77, Issue 2, pp. 216 - 220
This study shows that combinations of bryostatin 1, a novel modulator of protein kinase C currently under clinical evaluation, with the anti-oestrogenic agent... 
Protein kinase C | Synergy | Tamoxifen | Bryostatin | PROTEIN-KINASE-C | synergy | ONCOLOGY | bryostatin | AGENTS | DIFFERENTIATION | PHORBOL ESTER | PHASE-I | CANCER | tamoxifen | protein kinase C | LINES
Journal Article
International Journal of Gynecological Cancer, ISSN 1048-891X, 07/1996, Volume 6, Issue 4, pp. 273 - 278
The dose intensity of chemotherapy is an important factor in the treatment of patients with ovarian cancer, and a role for hemopoietic growth factors in... 
ovarian | c‐kit | stem cell factor | c-kit
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.